Equity - Additional Information (Details)									12 Months Ended
	Sep. 08, 2022 USD ($)	May 18, 2022 USD ($) $ / shares shares	Mar. 01, 2022 USD ($) $ / shares shares	Mar. 16, 2020 USD ($) $ / shares shares	Jan. 09, 2020 USD ($) $ / shares shares	Nov. 04, 2019 USD ($) $ / shares shares	May 31, 2019 USD ($) $ / shares shares	Feb. 15, 2019 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Jul. 16, 2021 $ / shares		Jul. 14, 2021 shares	Nov. 01, 2019 $ / shares shares	May 29, 2019 $ / shares shares	May 07, 2018 $ / shares shares
Stockholders Equity Details [Line Items]
Common stock, shares authorized									730,000,000	730,000,000				110,000,000
Common stock, par value (in Dollars per share) | $ / shares									$ 0.0001	$ 0.0001		$ 0.0001
Common stock, voting Rights									common stock are entitled to one vote per share
Preferred stock, shares authorized									10,000,000	10,000,000
Preferred stock, shares issued									0	0
Preferred stock, shares outstanding									0	0
Preferred stock, voting rights									Preferred Stock were entitled to vote
Dividend accrued on preferred stock, percentage									6.00%
Cash dividends declared or paid | $									$ 0
Preferred stock dividend payment description									The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of 6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date, no cash dividends were declared or paid.
Warrants outstanding to purchase shares of common stock			13,281,386
Proceeds from the exercise of warrants | $									$ 46,491,000
Number of shares issued			13,281,386
Change in fair value of warrant liabilities | $									$ (42,109,000)	$ (13,482,000)
Class of warrant or right, outstanding									33,458,360
Proceeds from PIPE financing | $									$ 30,000,000	83,400,000
Fair value of the warrant liability | $									$ 3,598,000	$ 25,962,000	$ 76,640,000
Legacy GX Warrants
Stockholders Equity Details [Line Items]
Description of exercisable terms									The Public Warrants became exercisable on August 15, 2021, which is the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the effective date of the registration statement relating to GX’s initial public offering.
Warrants
Stockholders Equity Details [Line Items]
Warrants exercisable date										Aug. 15, 2021
Warrants exercisable period after consummation of business combination										30 days
Warrants exercisable period from effective date of registration statement of initial public offering										12 months
Public warrants exercisable for cash										0
Warrant term										5 years
Call price of public warrants | $ / shares										$ 0.01
Minimum prior written notice period for redemption										30 days
Description of call provision									at any time while the Public Warrants are exercisable,•upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder, and•if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.
ATM Agreement
Stockholders Equity Details [Line Items]
Sales agents commission rate									3.00%
Gross Proceeds From Issuance Of Common Stock | $									$ 6,519,000
Net proceeds from sale of common stock | $									$ 6,021,000
May 2022 PIPE Warrants
Stockholders Equity Details [Line Items]
Exercise per share price (in Dollars per share) | $ / shares									$ 8.25
Class of warrant or right, outstanding									4,054,055
Warrants and rights outstanding, expire date									May 20, 2027
May 2022 PIPE Warrants | Private Placement
Stockholders Equity Details [Line Items]
Exercise per share price (in Dollars per share) | $ / shares		$ 8.25
Proceeds from PIPE financing | $		$ 30,000,000
Net related cost | $		27,396,000
Reduction to additional paid in capital | $		(2,604,000)
Proceeds from issuance of private placement in additional paid in capital, net | $		$ 7,651,000
Warrants and rights outstanding, expire date		May 20, 2027
Warrants and Rights Outstanding, Term		5 years
Warrants and rights issued closing date		May 20, 2022
Fair value of the warrant liability | $		$ 19,745,000
Sponsors
Stockholders Equity Details [Line Items]
Aggregate number of warrants issued to sponsor as repayment for working capital loans										1,499,999
Legacy Celularity
Stockholders Equity Details [Line Items]
Common stock, shares authorized											155,640,290
Common stock, par value (in Dollars per share) | $ / shares											$ 0.0001
Common stock, voting Rights											common stock entitled the holder to one vote
Treasury stock, Shares											90,834
Conversion of preferred stock, description									The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $6.27 for Series A and X Preferred Stock (the “Series A and X Original Issue Price”) and $7.53 for Series B Preferred Stock (the “Series B Original Issue Price”), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity’s certificate of incorporation, as amended and restated. As of December 31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December 31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a one-for-one basis.
Conversion ratio of preferred stock											1
Issuance cost of equity | $			$ 15,985,000
Legacy Celularity | Series B Preferred Stock Purchase Agreement [Member] | Warrants
Stockholders Equity Details [Line Items]
Proceeds from the issuance of equity and warrants | $				$ 17,954,000
Minimum
Stockholders Equity Details [Line Items]
Exercise per share price (in Dollars per share) | $ / shares			$ 3.50
Minimum | Preferred Stock
Stockholders Equity Details [Line Items]
Percentage of shares required for voting									50.00%
Minimum | Legacy Celularity | Preferred Stock
Stockholders Equity Details [Line Items]
Gross proceeds | $									$ 50,000,000
Conversion price per share of common stock | $ / shares									$ 9.41
Maximum
Stockholders Equity Details [Line Items]
Exercise per share price (in Dollars per share) | $ / shares			$ 7.53
Common Stock | ATM Agreement
Stockholders Equity Details [Line Items]
Aggregate Offering Price | $	$ 150,000,000
Sale of shares									2,656,413
Average price per share | $ / shares									$ 2.45
Class A Common Stock
Stockholders Equity Details [Line Items]
Common stock, shares authorized									730,000,000	730,000,000
Common stock, par value (in Dollars per share) | $ / shares									$ 0.0001	$ 0.0001		0.0001
Proceeds from the exercise of warrants | $			$ 46,485,000
Class of warrant or right, outstanding									33,458,360
Class A Common Stock | May 2022 PIPE Warrants | Private Placement
Stockholders Equity Details [Line Items]
Sale of shares		4,054,055
Warrants outstanding to purchase shares of common stock		4,054,055
Share price (in Dollars per share) | $ / shares		$ 7.40
Redeemable Convertible Preferred Stock
Stockholders Equity Details [Line Items]
Temporary equity, shares undesignated											0
Redeemable Convertible Preferred Stock | Legacy Celularity
Stockholders Equity Details [Line Items]
Warrants to purchase redeemable convertible preferred stock, shares authorized											116,526,341
Redeemable convertible preferred stock, par value (in Dollars per share) | $ / shares											$ 0.0001
Series B Redeemable Convertible Preferred Stock | Dragasac Warrant
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock																	16,601,736
Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Dragasac Warrant
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock						6,529,818	3,431,223	6,640,695
Exercise per share price (in Dollars per share) | $ / shares						$ 6.77	$ 7.29	$ 7.53									$ 7.53
Proceeds from the exercise of warrants | $						$ 44,178,000	$ 25,000,000	$ 50,000,000
Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Amended and Restated Dragasac Warrant
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock																3,431,223
Exercise per share price (in Dollars per share) | $ / shares																$ 7.29
Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Amended Dragasac Warrant
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock															6,529,818
Exercise per share price (in Dollars per share) | $ / shares															$ 6.77
Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Series B Preferred Stock Purchase Agreement [Member]
Stockholders Equity Details [Line Items]
Warrants to purchase redeemable convertible preferred stock, shares authorized				13,281,386
Redeemable convertible preferred stock, shares issued				13,620,063
Proceeds from the issuance of equity and warrants | $				$ 84,596,000
Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Series B Preferred Stock Purchase Agreement [Member] | Warrants
Stockholders Equity Details [Line Items]
Proceeds from the issuance of equity and warrants | $				$ 102,550,000
Series B Preferred Stock Purchase Agreement [Member] | Minimum | Legacy Celularity
Stockholders Equity Details [Line Items]
Number of shares required to be outstanding for voting									5,000,000
Series A Redeemable Convertible Preferred Stocks | Legacy Celularity
Stockholders Equity Details [Line Items]
Purchase price | $ / shares									$ 6.27
Series X Redeemable Convertible Preferred Stock | Legacy Celularity
Stockholders Equity Details [Line Items]
Purchase price | $ / shares									6.27
Series B Redeemable Convertible Preferred Stock | Legacy Celularity
Stockholders Equity Details [Line Items]
Purchase price | $ / shares									7.53
Series B Preferred Stock
Stockholders Equity Details [Line Items]
Exercise per share price (in Dollars per share) | $ / shares									$ 7.53			$ 7.53	[1]
Warrants and Rights Outstanding, Term												3 years 8 months 1 day
Series B Preferred Stock | Legacy Celularity | Investors [Member]
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock				13,281,386
Exercise per share price (in Dollars per share) | $ / shares				$ 7.53
Aggregate of shares				13,620,063
Series B Preferred Stock | Legacy Celularity | Investors [Member] | Warrants
Stockholders Equity Details [Line Items]
Proceeds from the issuance of equity and warrants | $				$ 102,550,000
Series B Preferred Stock | Legacy Celularity | Dragasac Warrant
Stockholders Equity Details [Line Items]
Warrants outstanding to purchase shares of common stock					6,529,818
Exercise per share price (in Dollars per share) | $ / shares					$ 6.77
Warrants per share, percentage					80.00%
Change in fair value of warrant liabilities | $					$ 11,988

[1] The warrants are exercisable at a price of $7.53 per share on the first to occur of: (a) the 60-month anniversary of the date of issuance of the warrants, (b) the consummation of an agreement for a public exit event, and (c) the consummation of a change of control.